Skip to main content
. Author manuscript; available in PMC: 2016 Jul 15.
Published in final edited form as: Cancer Res. 2015 May 12;75(14):2897–2906. doi: 10.1158/0008-5472.CAN-14-2860

Figure 3.

Figure 3

DNMT1 plays a role in mediating decitabine’s activity. A, cell viability after treatment with decitabine (AUC, x-axis) was plotted against DNMT1 mRNA expression (log2, y-axis). B, western blot analysis was performed after treatment with decitabine (0.5 µM) or DMSO for nine days in two KRAS-mutant ovarian cancer cell lines. C, DNMT1 protein level was probed by western blot after treatment with selumetinib for six days in two KRAS-mutant ovarian cancer cell lines. Data are representative of two independent experiments.